Skip to content
No results
  • About Us
  • Contact Us
  • Disclaimer
  • Events and Conferences
  • Home
  • Organizer Dashboard
  • Privacy Policy
  • Submit Organizer Form
  • Submit Venue Form
  • Subscribe
  • Terms and Conditions
  • Venue Dashboard
  • About Us
  • Contact Us
The Pharma Data

  • News
  • Press Releases
  • Research
  • Business
  • Regulatory
  • Events and Conferences
The Pharma Data
  • News

CHMP Recommends Third Indication for Bayer’s Nubeqa in Advanced Prostate Cancer Patients

  • The Pharma Data
  • June 21, 2025

CHMP Recommends Expanded Use of Bayer’s Nubeqa™ (Darolutamide) for Advanced Prostate Cancer Following Positive ARANOTE Trial Results The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines…

Read MoreCHMP Recommends Third Indication for Bayer’s Nubeqa in Advanced Prostate Cancer Patients
  • NewsResearch

Vertex Reports Favorable Zimislecel Outcomes for Type 1 Diabetes at ADA Scientific Sessions

  • The Pharma Data
  • June 21, 2025

Vertex Showcases Groundbreaking Data for Zimislecel in Type 1 Diabetes at ADA 85th Scientific Sessions Vertex Pharmaceuticals Incorporated has announced compelling new clinical data from its ongoing FORWARD-101 trial, underscoring…

Read MoreVertex Reports Favorable Zimislecel Outcomes for Type 1 Diabetes at ADA Scientific Sessions
  • News

FDA Approves Dupixent as First and Only Targeted Therapy for Bullous Pemphigoid in the US

  • The Pharma Data
  • June 21, 2025

FDA Approves Dupixent as the First and Only Targeted Therapy for Adults with Bullous Pemphigoid In a groundbreaking development for patients suffering from a rare and debilitating autoimmune skin disease,…

Read MoreFDA Approves Dupixent as First and Only Targeted Therapy for Bullous Pemphigoid in the US
  • News

Combination of Lunsumio and Polivy from Roche Significantly Extends Remission in R/R Large B-Cell Lymphoma

  • The Pharma Data
  • June 21, 2025

Roche’s Lunsumio and Polivy Combination Marks Major Advance in Relapsed or Refractory Large B-Cell Lymphoma with Significant Remission Durability Roche has announced promising results from its pivotal Phase III SUNMO…

Read MoreCombination of Lunsumio and Polivy from Roche Significantly Extends Remission in R/R Large B-Cell Lymphoma
  • Press Releases

H20 Summit to Shape G20 Health Agenda and Financing

  • The Pharma Data
  • June 20, 2025

Rebuilding Trust and Reshaping Global Health Finance: H20 Summit Lays Groundwork for G20 Health Agenda From June 19 to 20, global leaders in health and development converged in Geneva for…

Read MoreH20 Summit to Shape G20 Health Agenda and Financing
  • News

Civil Society Drives Global Health Agenda at WHA78

  • The Pharma Data
  • June 20, 2025

Civil Society Deepens Its Role in Shaping Global Health Policy at WHA78 At the 78th World Health Assembly (WHA78), held under the unifying theme “One World for Health,” a pivotal…

Read MoreCivil Society Drives Global Health Agenda at WHA78
  • News

Grifols’ Fibrinogen Phase 3 Results Published in eClinicalMedicine

  • The Pharma Data
  • June 20, 2025

Grifols’ BT524 Fibrinogen Therapy Shows Promise in Phase 3 Trial Published in The Lancet’s eClinicalMedicine Grifols, a globally recognized healthcare company and a leader in the production of plasma-derived therapies,…

Read MoreGrifols’ Fibrinogen Phase 3 Results Published in eClinicalMedicine
  • News

Alnylam Promotes Pushkal Garg to Chief R&D Officer

  • The Pharma Data
  • June 19, 2025

Alnylam Elevates Dr. Pushkal Garg to Lead Unified Research and Development Organization, Signaling Strategic Expansion into Next Phase of RNAi Therapeutics Innovation Alnylam Pharmaceuticals, a global leader in RNA interference…

Read MoreAlnylam Promotes Pushkal Garg to Chief R&D Officer
  • ResearchNews

Biogen Launches Phase 3 Pediatric Trial of Omaveloxolone for Friedreich Ataxia

  • The Pharma Data
  • June 19, 2025

Biogen Launches Global Phase 3 Pediatric Trial of Omaveloxolone for Friedreich Ataxia Biogen has officially launched its BRAVE study a pivotal, global Phase 3 clinical trial aimed at evaluating omaveloxolone…

Read MoreBiogen Launches Phase 3 Pediatric Trial of Omaveloxolone for Friedreich Ataxia
  • Press Releases

Merck Names Neoclease Winner of 2025 Biotech Grant

  • The Pharma Data
  • June 19, 2025

Merck Awards 2025 North American Advance Biotech Grant to Neoclease for AI-Driven Parkinson’s Gene Editing Therapy Merck, a global leader in science and technology, has officially named Neoclease as the…

Read MoreMerck Names Neoclease Winner of 2025 Biotech Grant
  • News

Amgen to Present Phase 2 Maritide Data at ADA 85th Scientific Sessions

  • The Pharma Data
  • June 19, 2025

Amgen to Unveil Full Phase 2 MariTide Data and Cardiometabolic Research Highlights at ADA 2025 Scientific Sessions Amgen has announced that it will present comprehensive data from Part 1 of…

Read MoreAmgen to Present Phase 2 Maritide Data at ADA 85th Scientific Sessions
  • Research

Phase 3 Trial of Ifinatamab Deruxtecan Begins in Advanced Prostate Cancer

  • The Pharma Data
  • June 19, 2025

Phase 3 Trial Launches for Ifinatamab Deruxtecan in Advanced Prostate Cancer Patients Daiichi Sankyo and Merck have announced the initiation of IDeate-Prostate01, a global Phase 3 clinical trial evaluating the…

Read MorePhase 3 Trial of Ifinatamab Deruxtecan Begins in Advanced Prostate Cancer
Next

About

The Pharma Data is an Information-Centric Website focused mainly on the Pharmaceutical Industry Online It is a B2B Platform mainly focused on the latest Pharmaceutical News, Press releases, Industry-related updates, Events, and Conferences. With The Pharma Data, you can get all the information that happening in the Pharmaceutical industry.

Advertise With Us: [email protected]

Latest Posts

  • CHMP Recommends Third Indication for Bayer’s Nubeqa in Advanced Prostate Cancer Patients
  • Vertex Reports Favorable Zimislecel Outcomes for Type 1 Diabetes at ADA Scientific Sessions
  • FDA Approves Dupixent as First and Only Targeted Therapy for Bullous Pemphigoid in the US
  • About Us
  • Disclaimer
  • Privacy Policy
  • Terms and Conditions
  • Contact Us

Copyright © 2025 | The Pharma Data | All Rights Reserved.